Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | May 09, 2017 | May 11, 2017 |
| MORGAN STANLEYMWD · Entity 2815 | Director | March 15, 2005 | March 17, 2005 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date May 09, 2017 · Filed May 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,548 |
Reported balance
After 2017-05-09 transaction · row 1
1 source rowRow 1 · 2017-05-09 · Exercise / conversion · Acquired 1,787 · Balance 18,548 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-05-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-05-09 · Exercise / conversion · Disposed 1,787 · Balance 0 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: 100% of the restricted stock units vested on May 9, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: 100% of the restricted stock units vested on May 9, 2017.
MORGAN STANLEY
Report date March 15, 2005 · Filed March 17, 2005
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,878.308 |
Ending reported balance
After 2005-03-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2005-03-15 · Grant · Acquired 4,000 · Balance 13,270.125 F1: Stock Units acquired under the deferred compensation provisions of Morgan Stanley's Directors' Equity Capital Accumulation Plan, which are convertible into shares of Common Stock at a ratio of 1 to 1. Row 2 · 2005-03-15 · Grant · Acquired 1,608.183 · Balance 14,878.308 F1: Stock Units acquired under the deferred compensation provisions of Morgan Stanley's Directors' Equity Capital Accumulation Plan, which are convertible into shares of Common Stock at a ratio of 1 to 1. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock Units acquired under the deferred compensation provisions of Morgan Stanley's Directors' Equity Capital Accumulation Plan, which are convertible into shares of Common Stock at a ratio of 1 to 1.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2017 Filed May 11, 2017 22:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-017796 · form4.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,787 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 9, 2017. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 9, 2017. Read SEC document |
| May 09, 2017 Filed May 11, 2017 22:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-17-017796 · form4.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 19:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001127602-16-068059 · form4.xml · derivative · entry 3 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2017-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested in full on May 9, 2007, the date of grant. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 19:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 105,000 | $74.86 | $7,860,058.50 |
DisclosureSEC source: 0001127602-16-068059 · form4.xml · nonDerivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,761 F2 · price: Sale prices reported for the transactions reported here range from $74.55 to $75.18. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 19:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 105,000 | $20.71 | $2,174,025.00 |
DisclosureSEC source: 0001127602-16-068059 · form4.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2016 Filed May 13, 2016 23:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 7,321 | $0.00 Strike: $83.90 | $0.00 |
DisclosureSEC source: 0001127602-16-052227 · form4.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,321 Underlying: Common Stock · 7,321 shares Expires 2026-05-11 F3 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 11, 2016 Filed May 13, 2016 23:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-052227 · form4.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,787 Underlying: Common Stock · 1,787 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 11, 2017, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2016 Filed May 10, 2016 20:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-051677 · form4.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2016. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2016. Read SEC document |
| May 06, 2016 Filed May 10, 2016 20:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-051677 · form4.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 06, 2015 Filed May 7, 2015 21:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 5,167 | $0.00 Strike: $102.27 | $0.00 |
DisclosureSEC source: 0001179110-15-007271 · edgar.xml · derivative · entry 4 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,167 Underlying: Common Stock · 5,167 shares Expires 2025-05-06 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2015 Filed May 7, 2015 21:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 1,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007271 · edgar.xml · derivative · entry 3 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,466 Underlying: Common Stock · 1,466 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 6, 2016, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 05, 2015 Filed May 7, 2015 21:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007271 · edgar.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 5, 2015. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 5, 2015. Read SEC document |
| May 05, 2015 Filed May 7, 2015 21:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-15-007271 · edgar.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 07, 2014 Filed May 9, 2014 00:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 4,868 | $0.00 Strike: $78.77 | $0.00 |
DisclosureSEC source: 0001179110-14-008019 · edgar.xml · derivative · entry 4 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,868 Underlying: Common Stock · 4,868 shares Expires 2024-05-07 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 07, 2014 Filed May 9, 2014 00:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008019 · edgar.xml · derivative · entry 3 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,904 Underlying: Common Stock · 1,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2014 Filed May 9, 2014 00:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008019 · edgar.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2014. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2014. Read SEC document |
| May 06, 2014 Filed May 9, 2014 00:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008019 · edgar.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 27, 2013 Filed Dec 6, 2013 23:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 25,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-017581 · edgar.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,528 F1 · kind: Shares gifted to charitable organizations. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 21:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 24,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-13-012466 · edgar.xml · derivative · entry 7 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2016-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 21:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 105,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001179110-13-012466 · edgar.xml · derivative · entry 6 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2016-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 21:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 120,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001179110-13-012466 · edgar.xml · derivative · entry 5 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2015-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vest annually over a period of two years from the grant date. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 21:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 249,000 | $61.97 | $15,430,654.50 |
DisclosureSEC source: 0001179110-13-012466 · edgar.xml · nonDerivative · entry 4 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,580 F3 · price: Sale prices reported for the transactions reported here range from $61.97 to $62.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 21:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 105,000 | $14.34 | $1,505,437.50 |
DisclosureSEC source: 0001179110-13-012466 · edgar.xml · nonDerivative · entry 3 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 21:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 120,000 | $13.00 | $1,559,400.00 |
DisclosureSEC source: 0001179110-13-012466 · edgar.xml · nonDerivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2013 Filed Aug 1, 2013 21:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 24,000 | $14.34 | $344,160.00 |
DisclosureSEC source: 0001179110-13-012466 · edgar.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2013 Filed May 14, 2013 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 5,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008384 · edgar.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,863 Underlying: Common Stock · 5,852 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 10, 2013, at the end of the first year of service. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 10, 2013, at the end of the first year of service. Read SEC document |
| May 10, 2013 Filed May 14, 2013 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008384 · edgar.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 08, 2013 Filed May 10, 2013 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008230 · edgar.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,715 Underlying: Common Stock · 2,863 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 08, 2013 Filed May 10, 2013 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 8,442 | $0.00 Strike: $52.38 | $0.00 |
DisclosureSEC source: 0001179110-13-008230 · edgar.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,442 Underlying: Common Stock · 8,442 shares Expires 2023-05-08 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2012 Filed May 16, 2012 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008472 · edgar.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,926 Underlying: Common Stock · 3,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 12, 2012, at the end of the first year of service. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 12, 2012, at the end of the first year of service. Read SEC document |
| May 12, 2012 Filed May 16, 2012 00:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008472 · edgar.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008420 · edgar.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,558 Underlying: Common Stock · 2,926 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 8,161 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001179110-12-008420 · edgar.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,161 Underlying: Common Stock · 8,161 shares Expires 2022-05-10 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 10, 2013. Read SEC document |
| May 12, 2011 Filed May 14, 2011 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,623 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007988 · edgar.xml · derivative · entry 4 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,623 Underlying: Common Stock · 3,623 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. Read SEC document |
| May 12, 2011 Filed May 14, 2011 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 10,141 | $0.00 Strike: $41.29 | $0.00 |
DisclosureSEC source: 0001179110-11-007988 · edgar.xml · derivative · entry 3 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,141 Underlying: Common Stock · 10,141 shares Expires 2021-05-12 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 12, 2012. Read SEC document |
| May 11, 2011 Filed May 14, 2011 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007988 · edgar.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2011 Filed May 14, 2011 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007988 · edgar.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008590 · edgar.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,820 Underlying: Common Stock · 3,820 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 10,860 | $0.00 Strike: $39.26 | $0.00 |
DisclosureSEC source: 0001179110-10-008590 · edgar.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,860 Underlying: Common Stock · 10,860 shares Expires 2020-05-11 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 11, 2011. Read SEC document |
| May 06, 2010 Filed May 10, 2010 21:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 3,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008261 · edgar.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,412 F1 · shares: Issuance of common stock upon vesting of certain restricted share units on May 6, 2010. Read SEC document |
| May 06, 2009 Filed May 8, 2009 23:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-09-007482 · edgar.xml · derivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,406 Underlying: Common Stock · 3,406 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 6, 2010, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 6, 2010, at the end of the first year of service. Read SEC document |
| May 06, 2009 Filed May 8, 2009 23:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 9,534 | $0.00 Strike: $44.03 | $0.00 |
DisclosureSEC source: 0001179110-09-007482 · edgar.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,534 Underlying: Common Stock · 9,534 shares Expires 2019-05-06 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 6, 2010. Read SEC document |
| May 08, 2008 Filed May 9, 2008 23:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (right to buy) · Derivative | 26,250 | $0.00 Strike: $53.23 | $0.00 |
DisclosureSEC source: 0001179110-08-009320 · edgar.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2018-05-08 F1 · derivative.exercise_date: Options vest quarterly over a period of one year from date of grant. Read SEC document |
| May 09, 2007 Filed May 11, 2007 23:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,250 | $0.00 Strike: $82.82 | $0.00 |
DisclosureSEC source: 0001179110-07-009847 · edgar.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2017-05-09 F1 · derivative.exercise_date: Options vested in full on May 9, 2007, the date of grant. Read SEC document |
| May 10, 2006 Filed May 12, 2006 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,250 | $0.00 Strike: $57.35 | $0.00 |
DisclosureSEC source: 0001179110-06-010649 · edgar.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2016-05-10 F1 · kind: Options are granted as part of the annual compensation to non-employee members of the Board of Directors and are immediately exercisable on date of grant. Read SEC document |
| January 26, 2006 Filed Jan 28, 2006 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $57.36 | $0.00 |
DisclosureSEC source: 0001179110-06-002224 · edgar.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2016-01-26 F1 · derivative.exercise_date: Options are 100% vested on date of grant. Read SEC document |
| December 12, 2005 Filed Dec 15, 2005 02:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $51.98 | $0.00 |
DisclosureSEC source: 0001179110-05-023003 · edgar.xml · derivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2015-12-12 F1 · kind: Granted pursuant to Gilead Sciences, Inc. 2004 Equity Incentive Plan in a transaction exempt from Rule 16b-3. F2 · derivative.exercise_date: Options vest annually over a period of two years from December 12, 2005, the date of grant. Read SEC document |
| March 15, 2005 Filed Mar 17, 2005 16:32 UTC | MORGAN STANLEY MWD · Entity 2815 | GrantCommon Stock | 1,608.183 | $58.85 | $94,641.57 |
DisclosureSEC source: 0001209191-05-016337 · doc4.xml · nonDerivative · entry 2 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,878.308 F1 · kind: Stock Units acquired under the deferred compensation provisions of Morgan Stanley's Directors' Equity Capital Accumulation Plan, which are convertible into shares of Common Stock at a ratio of 1 to 1. Read SEC document |
| March 15, 2005 Filed Mar 17, 2005 16:32 UTC | MORGAN STANLEY MWD · Entity 2815 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-05-016337 · doc4.xml · nonDerivative · entry 1 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,270.125 F1 · kind: Stock Units acquired under the deferred compensation provisions of Morgan Stanley's Directors' Equity Capital Accumulation Plan, which are convertible into shares of Common Stock at a ratio of 1 to 1. Read SEC document |
| April 20, 2004 Filed Apr 21, 2004 18:46 UTC | MORGAN STANLEY MWD · Entity 2815 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 1,979 | $17.68 Strike: $53.04 | $34,988.72 |
DisclosureSEC source: 0001204892-04-000063 · doc4.xml · derivative · entry 4 MADIGAN JOHN W · CIK 0001174463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,979 Underlying: Common Stock · 1,979 shares Expires 2014-04-20 F2 · kind: Stock options acquired under the deferred compensation provisions of DECAP. F3 · shares: In accordance with the deferred compensation provisions of DECAP, the number of DECAP stock options is determined by dividing the amount of the annual cash retainer by the fair market value of a share of Common Stock on the award date and multiplying the result by 3. F4 · price: In accordance with the deferred compensation provisions of DECAP, the deemed purchase price of each DECAP stock option is one-thi rd the fair market value of a share of Common Stock on the award date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.